Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CASR | P41180 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086556 | 0.91 | HIF1A (0.64) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL13572916 | 0.85 | TSHR (0.76) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL1496641 | 0.83 | ADRB2 (0.64) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL6256165 | 0.83 | MAPK1 (0.73) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL11276663 | 0.83 | TSHR (0.73) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL1496545 | 0.83 | TSHR (0.73) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL3630009 | 0.82 | AR (0.59) | MAPK1TSHRKDM4EL3MBTL1MAPT | |
| SCHEMBL29847698 | 0.81 | TSHR (0.70) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL1496491 | 0.81 | TSHR (0.70) | MAPK1TSHRKDM4EHIF1ATP53 | |
| SCHEMBL22640124 | 0.81 | KDM4E (1.00) | MAPK1TSHRKDM4EHIF1ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728179-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20090012330-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1982972-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012330-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | MAPK1 1367/4885TSHR 1213/4885KDM4E 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.